Literature DB >> 18422342

Structure of the covalent adduct formed between Mycobacterium tuberculosis beta-lactamase and clavulanate.

Lee W Tremblay1, Jean-Emmanuel Hugonnet, John S Blanchard.   

Abstract

The intrinsic resistance of Mycobacterium tuberculosis to the beta-lactam class of antibiotics arises from a chromosomally encoded, extended spectrum, class A beta-lactamase, BlaC. Herein, we report the X-ray crystallographic structure of BlaC inhibited with clavulanate at a resolution of 1.7 A with an R-factor value of 0.180 and R-free value of 0.212 for the m/ z +154 clavulanate-derived fragment observed in the active site. Structural evidence reveals the presence of hydrogen bonds to the C1 carbonyl along with a coplanar arrangement of C1, C2, C3, and N4, which favors enolization to generate a trans-alpha,beta-eneamine, stabilizing the +154 adduct from hydrolysis. The irreversible inhibition of BlaC suggests that treatment of M. tuberculosis with a combination of a beta-lactam antibiotic and clavulanate may lead to rapid bactericidal activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18422342     DOI: 10.1021/bi8001055

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  30 in total

Review 1.  The chemical biology of new drugs in the development for tuberculosis.

Authors:  Clifton E Barry; John S Blanchard
Journal:  Curr Opin Chem Biol       Date:  2010-05-07       Impact factor: 8.822

2.  Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo.

Authors:  Kathleen England; Helena I M Boshoff; Kriti Arora; Danielle Weiner; Emmanuel Dayao; Daniel Schimel; Laura E Via; Clifton E Barry
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

3.  Structures of the Michaelis complex (1.2 Å) and the covalent acyl intermediate (2.0 Å) of cefamandole bound in the active sites of the Mycobacterium tuberculosis β-lactamase K73A and E166A mutants.

Authors:  Lee W Tremblay; Hua Xu; John S Blanchard
Journal:  Biochemistry       Date:  2010-10-25       Impact factor: 3.162

4.  Strategies for discovering and derisking covalent, irreversible enzyme inhibitors.

Authors:  Douglas S Johnson; Eranthie Weerapana; Benjamin F Cravatt
Journal:  Future Med Chem       Date:  2010-06       Impact factor: 3.808

5.  β-Lactamase of Mycobacterium tuberculosis Shows Dynamics in the Active Site That Increase upon Inhibitor Binding.

Authors:  Wouter Elings; Anamika Gaur; Anneloes J Blok; Monika Timmer; Hugo van Ingen; Marcellus Ubbink
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

6.  Withdrawn

Authors: 
Journal:  Infect Disord Drug Targets       Date:  2012-11-16

7.  Crystal structure of L,D-transpeptidase LdtMt2 in complex with meropenem reveals the mechanism of carbapenem against Mycobacterium tuberculosis.

Authors:  Wen-Juan Li; De-Feng Li; Yong-Lin Hu; Xian-En Zhang; Li-Jun Bi; Da-Cheng Wang
Journal:  Cell Res       Date:  2013-04-16       Impact factor: 25.617

8.  Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.

Authors:  L Davies Forsman; C G Giske; J Bruchfeld; T Schön; P Juréen; K Ängeby
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

9.  Combinatorial active-site variants confer sustained clavulanate resistance in BlaC β-lactamase from Mycobacterium tuberculosis.

Authors:  Philippe Egesborg; Hélène Carlettini; Jordan P Volpato; Nicolas Doucet
Journal:  Protein Sci       Date:  2014-12-30       Impact factor: 6.725

10.  Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus.

Authors:  Amit Kaushik; Nayani Makkar; Pooja Pandey; Nicole Parrish; Urvashi Singh; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.